Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Osteosarcoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Dendritic Cell Sarcoma, Interdigitating 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Metformin × Sarcoma × Clear all
NCT05854966 2024-09-19

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Wake Forest University Health Sciences

Phase 2 Withdrawn
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡